Cardiotoxicity of Non-Cardiovascular Drugs

Some drugs which are not aimed at treating heart diseases have nevertheless been found to have profound effects on the cardiovascular system. Cardiotoxicity is one of the major untoward effects of drugs and it accounts for most drug recalls and delays experienced in regulatory approvals. In recent years a number of non-cardiac blockbuster drugs have been withdrawn from major markets because of cardiotoxicity concerns, while other drugs have either been halted prior to marketing or required labelling changes that significantly restricted their use.

In Cardiotoxicity of Non-Cardiovascular Drugs international experts describe the molecular mechanisms and clinical read-outs of cardiac events induced by a broad variety of noncardiovascular drugs. Emphasis is also paid to the preclinical screening of drug cardiotoxicity.

Topics include:

• metabolic targets of cardiotoxicity
• regulatory aspects
• cellular mechanisms, molecular targets and structure-activity relationships in arrhythmias by antihistamines, psychoactive drugs and antimicrobial agents
• cardiovascular toxicity of antitumor drugs
• cardiovascular toxicities of non-steroidal anti-inflammatory drugs
• cardiovascular toxicities of antiretroviral therapies

Cardiotoxicity of Non-Cardiovascular Drugs is an essential guide to this important area of drug development and surveillance. It will find a place on the bookshelves of basic and clinical researchers, regulators, and students interested in oncology, cardiology, pharmacology, medicinal chemistry and drug development.